The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR)
Autor: | Cecilia Martelli, Elisabetta Teodori, Serena Scapecchi, Silvia Dei, Fulvio Gualtieri |
---|---|
Rok vydání: | 2006 |
Předmět: |
Models
Molecular Clinical Biochemistry Cell ATP-binding cassette transporter Computational biology Pharmacology Biology Membrane Transport Modulators Drug Discovery medicine Humans ATP Binding Cassette Transporter Subfamily B Member 1 Clinical Trials as Topic Molecular Structure Transporter Small molecule Drug Resistance Multiple Multiple drug resistance medicine.anatomical_structure Mechanism of action Drug Design Cancer cell Molecular Medicine ATP-Binding Cassette Transporters medicine.symptom Multidrug Resistance-Associated Proteins Energy source QacR repressor protein Stipiamide homodimers Vasodilatant Acti Negative Chronotropic Activity Negative Inotropic Activity Tropane alkaloids Idarubicin activity P-gp expression THPadriamycin Ipophilicity CYP3A4 Dihydropyridines Quinidine Cyclosporin A Quinine derivatives Acridone carboxamides Triazines Phenoxazines Vinca alkaloid analogues Pyridine analogues Immunomodulators Antiarrhythmic agents Calmodulin antagonists ABC Modulators Sav1866 Nucleotide binding domains (NBDs) Transmembrane domains (TMDs) Breast cancer-resistance protein Anthracycline-resistant erytroleukemia K562 ATP Binding Cassette (ABC) Pglycoprotein Transporter-Dependent Multidrug Resistance Verapamil P-gp inhibitors Pervilleine N N-bis(Cyclohexanol)amine aryl esters N N-bis(Alkanol)amine aryl esters Multidrug resistance reverters MDR-reversing activity K562/DOX cell line K562 cell line Chemosensitizers |
Zdroj: | Current drug targets. 7(7) |
ISSN: | 1389-4501 |
Popis: | Multidrug resistance (MDR) is a kind of acquired resistance of microorganisms and cancer cells to chemotherapic drugs that are characterized by different chemical structure and different mechanism of action. Classic MDR is the consequence of the over-expression of a variety of proteins that extrude the chemotherapic from the cell, lowering its concentration below the effective one. The ABC (ATP Binding Cassette) is a ubiquitous and important family of such transporter proteins. Members of this super family are present in mammals as well as in prokaryotic organisms and use ATP as the energy source to activate the extrusion process. P-glycoprotein (Pgp) and Multidrug Resistance Proteins (MRP1 and sister proteins) are the most important and widely studied members of ABC super family. Our knowledge about the structures and functions of transporter proteins has definitely improved in recent years, following the resolution of the structure of bacterial pumps which opened the way to the building of homology models for the more complex Pgp and MRP. It can be anticipated that these results will have a strong impact on the design of more potent and safer MDR reverters. A huge number of small molecules, many of natural origin, are able to reverse multidrug resistance by inhibiting the functions of Pgp, MRP1 and sister proteins and their action has been considered a possible way to reverse MDR. However, while a few compounds have reached clinical trials, none of them has, so far, been cleared for therapeutic use. Two main reasons are at the base of this difficulty: i) MDR is a complex phenomenon that may arise from several different biochemical mechanisms, with the consequence that inhibition of transporter proteins may be insufficient to reverse it; ii) the physiological role of Pgp and sister proteins requires more potent modulators with proper selectivity and pharmacokinetic in order to avoid unwanted side effects. This paper first reviews the most recent discoveries on the structures and functions of the ABC super family, in particular Pgp and MRP. Then, the medicinal chemistry of MDR reverters, in light of these findings, is discussed and the molecules that are presently in development are reviewed. |
Databáze: | OpenAIRE |
Externí odkaz: |